1. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480–91. https://doi.org/10.1111/jdv.12323.
2. Van Baalen J, Claassen N, Greving J, Wiersma T. NHG-Standaard Dermatomycosen (tweede herziening). Utrecht: Nederlands Huisartsen Genootschap; 2022. https://richtlijnen.nhg.org/standaarden/dermatomycosen, geraadpleegd juni 2023.
3. Lipner SR, Scher RK. Onychomycosis Clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835–51. https://doi.org/10.1016/j.jaad.2018.03.062.
4. Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7(7):CD010031. https://doi.org/10.1002/14651858.CD010031.pub2.
5. Szepietowski JC, Reich A, Garlowska E, Kulig M, Baran E. Onychomycosis Epidemiology Study G. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006;142(10):1279–84. https://doi.org/10.1001/archderm.142.10.1279.